Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study observed that both autogenic and xenogenic PRP improved graft viability in rabbits compared to control, with autogenic PRP showing better histopathological results.

In this study, PRP injections increased hair count and reduced hair loss in patients with androgenic alopecia not responding to minoxidil and finasteride, with high patient satisfaction reported.

This pilot study suggests injecting platelet-derived growth factors into the scalp may offer some clinical benefits for androgenetic alopecia, though further randomized trials are needed for confirmation.

In this study, personalized PRP therapy significantly increased hair density and diameter in a patient with androgenetic alopecia, highlighting its potential benefit but emphasizing the need for broader clinical trials.

Dutasteride reduces prostate cancer risk by 23% in high-risk men.

In this clinical trial, patients with lichen planopilaris treated with the oral TYK2 inhibitor deucravacitinib showed significant improvement in PGA, LPPAI, and Skindex-16 scores over 24 weeks, with transcriptomic analyses indicating decreased inflammatory and immune pathway activity post-treatment.

This study found that injections of autologous platelet-rich plasma in patients with pattern hair loss were compared to placebo, but the abstract does not report specific clinical results.

In this study, the researchers reported that a novel exosome-based treatment, EX104, effectively reversed hair follicle miniaturization and promoted hair growth in a mouse model of androgenetic alopecia, showing results comparable to minoxidil and surpassing it in stimulating capillary growth and follicular proliferation.

In this study, the novel topical agent PP405 showed favorable tolerability and increased hair density by over 20% in men with advanced androgenetic alopecia after eight weeks, suggesting a promising potential treatment pending further trials.

In this retrospective study, QR678 Neo, a biomimetic peptide treatment for androgenetic alopecia, improved hair density by 30% compared to 18% with platelet-rich plasma, with patients reporting higher satisfaction.

In this study, autologous non-activated platelet-rich plasma was associated with greater hair re-growth than autologous activated platelet-rich plasma over long-term follow-up.

This study found that platelet-rich plasma therapy may improve hair density and thickness in androgenetic alopecia, especially in early to moderate stages, though standardization of preparation is needed for consistent results.

This study concluded that finasteride is most cost-effective for prostate cancer chemoprevention when started at age 65 and continued until age 80.

This study found that a single injection of platelet-rich stroma significantly increased hair density in men with androgenetic alopecia within 6 to 12 weeks, with no reported side effects.

In a study on the effects of stromal vascular fraction (SVF) and platelet-rich plasma (PRP) on hair growth in nude mice, researchers found that both treatments promoted hair growth, with SVF showing a stronger effect.

This review discusses the use of platelet-rich plasma as a treatment for androgenetic alopecia and highlights the need for standardized protocols, reporting no new clinical results.

In this proof-of-concept study, researchers found that hair grafts preserved in preconditioned autologous platelet-rich plasma with photothermal biostimulation and phosphate-buffered saline remained viable for eight hours before transplantation, outperforming saline solution and Ringer's lactate by two hours.

This review synthesizes existing research on autologous platelet-rich plasma for treating androgenetic alopecia, suggesting its promise with standardized protocols and personalized approaches, but reports no new clinical results.

This study found that PRP is most commonly used for treating androgenetic alopecia and facial rejuvenation, with no serious adverse events reported among participants.

This study assessed the safety, efficacy, and feasibility of platelet-rich plasma injections in treating androgenetic alopecia, but it reports no clinical results.

In this study, platelet-rich plasma injections in mice promoted hair growth and angiogenesis compared to control, as evidenced by longer hair lengths and increased vessel formation.

Platelet-rich plasma (PRP) may help promote hair growth and improve graft survival after hair transplantation, but more research is needed to confirm its effectiveness and determine the best dosage.

This review indicates that most studies reported positive effects of platelet-rich plasma injections for treating androgenic alopecia, with no major side effects, suggesting it may be a safe alternative to Minoxidil and Finasteride.

This review discusses platelet-rich plasma treatment for androgenetic alopecia, addressing its effectiveness, challenges, and future directions, but reports no new clinical results.

PRP treatment showed no hair regrowth improvement after the first application in patients with alopecia.

This study concluded that administering 5-alpha reductase inhibitors before photoselective vaporization of the prostate increased hemoglobin change, lasing time, and energy required during the procedure compared to controls.

The study suggests that variability in platelet-derived growth factors in PRP is influenced by both patient-to-patient differences and the devices used for PRP preparation, contributing to inconsistent clinical outcomes in hair loss treatments.